Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 42(5): 302-309, sept.- oct. 2023. ilus, tab, graf
Article in Spanish | IBECS | ID: ibc-225088

ABSTRACT

Objetivo Determinar la contribución diagnóstica de la cuantificación absoluta del depósito miocárdico de 99mTc-DPD en pacientes con amiloidosis cardiaca por depósitos de transtiretina (ATTR). Materiales y métodos Se realizó SPECT/TC a 41 pacientes con resultado gammagráfico positivo para amiloidosis cardiaca ATTR. Se dividió a los pacientes en dos grupos (grados2 y3 de Perugini) y se calcularon los SUVmax a nivel del hueso y de ambos ventrículos y el porcentaje de dosis calculado en estas áreas. Se empleó la prueba t de Student para comparar resultados y se calculó el área bajo la curva (AUC) para evaluar la eficacia diferencial y establecer unos puntos de corte discriminatorios entre ambos grupos de pacientes. Resultados Se observaron diferencias estadísticamente significativas en todas las variables a estudio, a excepción del SUVmax hueso. Las diferencias con mayor potencia estadística se observaron en las variables SUVmaxVD y el porcentaje de dosis en ambos ventrículos (p<0,001). El punto de corte obtenido para la variable SUVmaxVI fue de 8,620 (sensibilidad del 87,9% y especificidad del 100%; AUC: 0,966), mientras que el de la variable SUVmaxVD fue de 6,195 (sensibilidad del 81,8% y especificidad del 100%; AUC: 0,955). Conclusiones La cuantificación absoluta de la captación miocárdica de 99mTc-DPD en las imágenes SPECT/TC de pacientes con sospecha de amiloidosis cardiaca por depósitos de transtiretina supone una nueva herramienta diagnóstica que permite una adecuada clasificación de los pacientes, acorde a la escala de gradación visual de Perugini (AU)


Purpose To determine the diagnostic contribution of the absolute quantification of the myocardial deposit of 99mTc-DPD in patients with cardiac amyloidosis due to transthyretin deposits (ATTR). Materials and methods SPECT/CT was performed on 41 patients with positive scintigraphic results for ATTR cardiac amyloidosis. The patients were divided into two groups (Perugini grades2 and3) and the SUVmax at the level of the bone and both ventricles and the percentage of dose calculated in these areas were calculated. Student's t-test was used to compare results and the area under the curve (AUC) was calculated to assess differential efficacy and establish discriminatory cut-off points between both groups of patients. Results Statistically significant differences were observed in all the study variables, with the exception of SUVmax bone. The differences with the greatest statistical power were observed in the variables SUVmaxRV and the percentage of dose in both ventricles (P<.001). The cut-off point obtained for the variable SUVmaxLV was 8.620 (sensitivity 87.9% and specificity 100%; AUC: 0.966), while that of the variable SUVmaxRV was 6.195 (sensitivity 81.8% and specificity 100%; AUC: 0.955). Conclusions The absolute quantification of myocardial uptake of 99mTc-DPD in the SPECT/CT images of patients with suspected cardiac amyloidosis due to transthyretin deposits represents a new diagnostic tool that allows an adequate classification of patients, according to the visual grading scale of Perugini (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Amyloidosis/diagnostic imaging , Heart Diseases/diagnostic imaging , Prealbumin/analysis , Single Photon Emission Computed Tomography Computed Tomography
5.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 39(4): 254-266, jul.-ago. 2020. ilus, tab, graf
Article in Spanish | IBECS | ID: ibc-198286

ABSTRACT

La amiloidosis cardíaca relacionada con el depósito de transtirretina (ATTR) ha sido tradicionalmente considerada como una enfermedad rara, de difícil diagnóstico y sin tratamiento. Sin embargo, en la actualidad sabemos que su prevalencia es mayor de la considerada, disponemos de métodos diagnósticos no invasivos y están apareciendo tratamientos eficaces. En este contexto, la gammagrafía cardíaca (GC) con difosfonatos marcados con 99mTc ha alcanzado un inusitado interés al mostrar alta sensibilidad y especificidad para el diagnóstico no invasivo y fiable de la ATTR. Este artículo, a modo de guía, pretende identificar los componentes críticos en la realización de la GC que resulten de utilidad en la práctica clínica diaria y, así, ayudar a los especialistas a utilizar los radiofármacos idóneos, obtener las imágenes más adecuadas, interpretar los resultados de estas y conocer los escenarios clínicos en los que resulta apropiado realizar la GC


Transthyretin cardiac amyloidosis (ATTR) has traditionally been considered a rare, difficult-to-diagnose and untreatable disease. However, its prevalence is known to be greater than what was previously thought, non-invasive diagnostic methods are available, and that effective treatments are emerging. In this context, cardiac scintigraphy (CS) with 99mTc-labelled diphosphonates has aroused a noticeable surge in interest by demonstrating high sensitivity and specificity for the reliable, non-invasive diagnosis of ATTR. By way of a guide, this article aims to identify the critical components in the performance of CS that are useful in everyday clinical practice and, thus, help specialists use optimal radiopharmaceuticals, obtain the most appropriate images, interpret the results thereof, and acquaint themselves with those clinical scenarios in which it is convenient to perform CS


Subject(s)
Humans , Radionuclide Imaging/methods , Prealbumin/analysis , Plaque, Amyloid/diagnostic imaging , Heart Diseases/diagnostic imaging , Diphosphonates/administration & dosage , Technetium/administration & dosage , Isotope Labeling/methods
7.
Article in English, Spanish | MEDLINE | ID: mdl-32513587

ABSTRACT

Transthyretin cardiac amyloidosis (ATTR) has traditionally been considered a rare, difficult-to-diagnose and untreatable disease. However, its prevalence is known to be greater than what was previously thought, non-invasive diagnostic methods are available, and that effective treatments are emerging. In this context, cardiac scintigraphy (CS) with 99mTc-labelled diphosphonates has aroused a noticeable surge in interest by demonstrating high sensitivity and specificity for the reliable, non-invasive diagnosis of ATTR. By way of a guide, this article aims to identify the critical components in the performance of CS that are useful in everyday clinical practice and, thus, help specialists use optimal radiopharmaceuticals, obtain the most appropriate images, interpret the results thereof, and acquaint themselves with those clinical scenarios in which it is convenient to perform CS.


Subject(s)
Amyloid Neuropathies, Familial/diagnostic imaging , Cardiomyopathies/diagnostic imaging , Diphosphonates , Organotechnetium Compounds , Radionuclide Imaging/methods , Radiopharmaceuticals , Technetium Tc 99m Medronate/analogs & derivatives , Technetium Tc 99m Pyrophosphate , Algorithms , Amyloid/chemistry , Amyloid Neuropathies, Familial/complications , Bone and Bones/diagnostic imaging , Calcinosis/diagnostic imaging , Calcinosis/etiology , Cardiomyopathies/complications , Clinical Protocols , Diphosphonates/administration & dosage , Diphosphonates/pharmacokinetics , Forms and Records Control , Heart/diagnostic imaging , Heart Failure/etiology , Humans , Mass Screening , Myocardium/metabolism , Myocardium/pathology , Organ Specificity , Organotechnetium Compounds/administration & dosage , Organotechnetium Compounds/pharmacokinetics , Prealbumin/genetics , Prognosis , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/pharmacokinetics , Technetium Tc 99m Medronate/administration & dosage , Technetium Tc 99m Medronate/pharmacokinetics , Technetium Tc 99m Pyrophosphate/administration & dosage , Technetium Tc 99m Pyrophosphate/pharmacokinetics , Whole Body Imaging/methods
8.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 38(4): 262-271, jul.-ago. 2019. ilus, tab
Article in Spanish | IBECS | ID: ibc-188706

ABSTRACT

La obtención de imágenes de la inervación simpática cardiaca solo es posible mediante técnicas de cardiología nuclear, y su valoración es de importancia decisiva en la evaluación y en la toma de decisiones en pacientes en los que exista deterioro de inervación simpática. Se revisa el fundamento de la gammagrafía de inervación simpática cardiaca con 123I-metayodobencilguanidina (123I-MIBG), los protocolos recomendados para su realización, incluyendo preparación del paciente, técnicas de obtención y cuantificación de imágenes, reproducibilidad, consideraciones dosimétricas, etc. , analizando las indicaciones clínicas de esta exploración en pacientes cardiológicos, principalmente en insuficiencia cardiaca, arritmias, coronariopatía, cardiotoxicidad, contribución a la indicación y seguimiento de respuesta a dispositivos de estimulación cardiaca, tratamiento farmacológico, trasplante cardiaco y otros


Imaging of cardiac sympathetic innervation is only possible by nuclear cardiology techniques and its assessment is key in the evaluation of and decision-making for patients with cardiac sympathetic impairment. This review includes the basis of cardiac sympathetic scintigraphy with 123I-meta-iodobenzylguanidine (123I-MIBG), recommended protocols, patient preparation, image acquisition and quantification, reproducibility, dosimetry, etc. , and also the clinical indications for cardiac patients, mainly with regard to heart failure, arrhythmia, coronary artery disease, cardiotoxicity, including its contribution to establishing the indication for and monitoring the response to implantable cardiac devices, pharmacological treatment, heart transplantation and other


Subject(s)
Humans , Heart/innervation , Heart Conduction System/diagnostic imaging , Heart Diseases/diagnostic imaging , Radiopharmaceuticals/administration & dosage , Receptors, Adrenergic/physiology , Heart/diagnostic imaging , Heart Conduction System/physiopathology , Image Processing, Computer-Assisted , Radiopharmaceuticals/pharmacokinetics , Cardiac Resynchronization Therapy Devices , Prognosis
9.
Article in English, Spanish | MEDLINE | ID: mdl-31031167

ABSTRACT

Imaging of cardiac sympathetic innervation is only possible by nuclear cardiology techniques and its assessment is key in the evaluation of and decision-making for patients with cardiac sympathetic impairment. This review includes the basis of cardiac sympathetic scintigraphy with 123I-meta-iodobenzylguanidine (123I-MIBG), recommended protocols, patient preparation, image acquisition and quantification, reproducibility, dosimetry, etc., and also the clinical indications for cardiac patients, mainly with regard to heart failure, arrhythmia, coronary artery disease, cardiotoxicity, including its contribution to establishing the indication for and monitoring the response to implantable cardiac devices, pharmacological treatment, heart transplantation and other.


Subject(s)
3-Iodobenzylguanidine , Heart Conduction System/diagnostic imaging , Heart Diseases/diagnostic imaging , Heart/innervation , Iodine Radioisotopes , Radiopharmaceuticals , Sympathetic Nervous System/diagnostic imaging , 3-Iodobenzylguanidine/administration & dosage , 3-Iodobenzylguanidine/pharmacokinetics , Cardiac Resynchronization Therapy Devices , Child, Preschool , Clinical Decision-Making , Defibrillators, Implantable , Heart/diagnostic imaging , Heart Conduction System/physiopathology , Heart Diseases/chemically induced , Heart Diseases/physiopathology , Heart Transplantation , Humans , Image Processing, Computer-Assisted , Infusions, Intravenous , Iodine Radioisotopes/administration & dosage , Iodine Radioisotopes/pharmacokinetics , Norepinephrine/physiology , Perchlorates/administration & dosage , Potassium Compounds/administration & dosage , Prognosis , Radiometry , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/pharmacokinetics , Receptors, Adrenergic/physiology , Reproducibility of Results , Sympathetic Nervous System/physiopathology , Thyroid Gland/drug effects , Treatment Outcome
10.
Article in English, Spanish | MEDLINE | ID: mdl-30120068

ABSTRACT

Urinary leakage in patients with kidney transplantation is a relatively common surgical complication that requires early diagnosis and intervention. The isotopic renogram is a non-invasive and effective method to evaluate the perfusion and function of kidney transplantation, and allows us to diagnose urological complications such as urinary leakage. In these cases, it is useful to complete the study with planar images and delayed SPECT/CT to specify the diagnosis and locate the leak. We expose two cases diagnosed with urinary leak after performing a renogram with early and delayed planar images and delayed SPECT/CT a week after transplantation. In both cases, a percutaneous nephrostomy catheter was placed, as well as a double J catheter, resolving the surgical complication.


Subject(s)
Kidney Transplantation , Kidney/diagnostic imaging , Postoperative Complications/diagnostic imaging , Single Photon Emission Computed Tomography Computed Tomography , Urine , Urography , Aged , Female , Humans , Male , Middle Aged
11.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 37(1): 67-670, ene.-feb. 2018. tab
Article in Spanish | IBECS | ID: ibc-170036

ABSTRACT

Esta actualización pretende contextualizar la relevancia de la biopsia selectiva del ganglio centinela (BSGC) en mujeres con cáncer de mama e indicación de quimioterapia neoadyuvante (QTN). El Grupo de Trabajo de Cirugía Radioguiada de la SEMNIM es consciente de la variabilidad existente en nuestro país sobre todo en cuanto al momento de realizar la técnica (previa o tras la QTN) y en cuanto al manejo de pacientes con axila negativa o positiva al diagnóstico. Existe suficiente experiencia contrastada para aseverar que mediante técnicas radioisotópicas la BSGC es factible, eficaz y segura en estos escenarios. Una adecuada valoración mediante técnicas de imagen de la situación tumoral a nivel de la axila previa a la cirugía y la posibilidad del marcaje previo a la QTN de cualquier ganglio infiltrado deben ser los pilares fundamentales para garantizar el éxito de la BSGC. Es un hecho que incorporar la BSGC en el cáncer de mama con indicación de QTN favorece un tratamiento conservador de la axila, lo cual redunda en claro beneficio de las pacientes (AU)


The role of the selective sentinel node biopsy (SNB) is increasing in relevance in breast cancer women with indication of neoadjuvant chemotherapy (NAC). The Radiosurgery Working Group of the SEMNIM is aware of the necessity of establishing the need for SNB before or after NAC, and also how to manage patients with axillary node-negative or node-positive. There is sufficient data to assess that the SNB with radioisotope techniques are feasible and safe in all these scenarios. An adequate axilla evaluation prior to surgery and the possibility of marking prior to NAC the nodes infiltrated must be the two main pillars to guarantee the success of the SNB. It has been shown that to incorporate the SNB in breast cancer women with indication of NAC increases the rate of a conservative treatment of the axilla that will be a clear benefit for these patients (AU)


Subject(s)
Humans , Sentinel Lymph Node Biopsy/methods , Breast Neoplasms/pathology , Lymphatic Metastasis/diagnosis , Neoadjuvant Therapy
12.
Article in English, Spanish | MEDLINE | ID: mdl-28869178

ABSTRACT

The role of the selective sentinel node biopsy (SNB) is increasing in relevance in breast cancer women with indication of neoadjuvant chemotherapy (NAC). The Radiosurgery Working Group of the SEMNIM is aware of the necessity of establishing the need for SNB before or after NAC, and also how to manage patients with axillary node-negative or node-positive. There is sufficient data to assess that the SNB with radioisotope techniques are feasible and safe in all these scenarios. An adequate axilla evaluation prior to surgery and the possibility of marking prior to NAC the nodes infiltrated must be the two main pillars to guarantee the success of the SNB. It has been shown that to incorporate the SNB in breast cancer women with indication of NAC increases the rate of a conservative treatment of the axilla that will be a clear benefit for these patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Lymphatic Metastasis/diagnostic imaging , Neoadjuvant Therapy , Sentinel Lymph Node Biopsy , Adult , Aged , Axilla , Breast Neoplasms/surgery , Clinical Trials as Topic , Combined Modality Therapy , Female , Humans , Lymph Node Excision , Mastectomy , Multicenter Studies as Topic , Sentinel Lymph Node Biopsy/methods , Unnecessary Procedures
13.
Radiología (Madr., Ed. impr.) ; 58(5): 352-365, sept.-oct. 2016. tab, ilus, graf
Article in Spanish | IBECS | ID: ibc-156292

ABSTRACT

El cáncer de esófago es un tumor de comportamiento agresivo, que suele diagnosticarse en etapas avanzadas. La ausencia de serosa permite su rápida propagación a estructuras vecinas del mediastino, y una extensa red de drenaje linfático facilita la diseminación tumoral incluso en estadios precoces. La actual clasificación TNM, armonizada con la del cáncer gástrico, proporciona nuevas definiciones en la clasificación anatómica, añade características no anatómicas del tumor e incluye los tumores de la unión esofagogástrica. La mayor precisión en la determinación del estadio clínico inicial se obtiene con la combinación de ecoendoscopia, TC, PET-TC y RM, que desempeñan un papel esencial en la elección, la planificación y la evaluación del tratamiento. En este artículo repasamos algunas particularidades que explican el comportamiento de este tumor, revisamos la estadificación TNM actual y presentamos las distintas pruebas de imagen de que disponemos en la actualidad para su evaluación, incluyendo un algoritmo de diagnóstico (AU)


Cancer of the esophagus is a tumor with aggressive behavior that is usually diagnosed in advanced stages. The absence of serosa allows it to spread quickly to neighboring mediastinal structures, and an extensive lymphatic drainage network facilitates tumor spread even in early stages. The current TNM classification, harmonized with the classification for gastric cancer, provides new definitions for the anatomic classification, adds non-anatomic characteristics of the tumor, and includes tumors of the gastroesophageal junction. Combining endoscopic ultrasound, computed tomography, positron emission tomography, and magnetic resonance imaging provides greater accuracy in determining the initial clinical stage, and these imaging techniques play an essential role in the selection, planning, and evaluation of treatment. In this article, we review some particularities that explain the behavior of this tumor and we describe the current TNM staging system; furthermore, we discuss the different imaging tests available for its evaluation and include a diagnostic algorithm (AU)


Subject(s)
Humans , Esophageal Neoplasms , Neoplasm Staging/methods , Diagnostic Imaging/methods , Esophagogastric Junction/anatomy & histology , Esophagoscopy/methods , Esophagectomy
14.
Radiologia ; 58(5): 352-65, 2016.
Article in English, Spanish | MEDLINE | ID: mdl-27469407

ABSTRACT

Cancer of the esophagus is a tumor with aggressive behavior that is usually diagnosed in advanced stages. The absence of serosa allows it to spread quickly to neighboring mediastinal structures, and an extensive lymphatic drainage network facilitates tumor spread even in early stages. The current TNM classification, harmonized with the classification for gastric cancer, provides new definitions for the anatomic classification, adds non-anatomic characteristics of the tumor, and includes tumors of the gastroesophageal junction. Combining endoscopic ultrasound, computed tomography, positron emission tomography, and magnetic resonance imaging provides greater accuracy in determining the initial clinical stage, and these imaging techniques play an essential role in the selection, planning, and evaluation of treatment. In this article, we review some particularities that explain the behavior of this tumor and we describe the current TNM staging system; furthermore, we discuss the different imaging tests available for its evaluation and include a diagnostic algorithm.


Subject(s)
Esophageal Neoplasms/diagnostic imaging , Esophageal Neoplasms/pathology , Algorithms , Humans , Lymphatic Metastasis , Magnetic Resonance Imaging , Neoplasm Staging , Tomography, X-Ray Computed
15.
Rev Esp Med Nucl Imagen Mol ; 31(4): 173-7, 2012.
Article in Spanish | MEDLINE | ID: mdl-23067685

ABSTRACT

UNLABELLED: The sentinel lymph node (SLN) biopsy is currently the procedure of choice for axillary node staging in initial stages of breast cancer. The purpose of this study is to establish our false negative rate within a 5-year follow-up period in 258 patients with breast cancer staged with this procedure. METHODS: A retrospective study on 258 consecutive T1-T2<3 cm pN0 staged breast carcinomas treated from January 1, 2001 to December 31, 2005 was performed. The combined technique of isotope plus blue dye was used for detection. The subjects underwent a minimum follow-up of 5 years, mean 81 months, with an end of follow-up at December 31, 2010. Evidence of axillary recurrence, tumor recurrence in the breast and signs of disease progression or death were the events collected and analyzed. RESULTS: Of the 258 patients, 3 false negatives (1.1%) with axillary recurrence were detected at 10, 11 and 29 months of the surgery. This did not have a significant repercussion in the survival analysis on the contrary to the existence of breast recurrence or the appearance of distant metastasis in 4.7% and 6.2% patients, respectively. Global survival related with the cancer was 93.0 (240/258) and disease free survival was 89.1% (230/258). CONCLUSION: The risk of developing axillary recurrence after a negative SLN without axillary node dissection is low enough to consider the SLN procedure to be the best approach for axilla staging in early breast cancer. This staging technique also makes it possible to achieve local disease control without diminishing the survival of the patients.


Subject(s)
Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/secondary , Lymphatic Metastasis , Sentinel Lymph Node Biopsy/statistics & numerical data , Adult , Aged , Aged, 80 and over , Axilla , Breast Neoplasms/surgery , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/diagnosis , Carcinoma, Ductal, Breast/epidemiology , Carcinoma, Ductal, Breast/surgery , Carcinoma, Lobular/diagnosis , Carcinoma, Lobular/epidemiology , Carcinoma, Lobular/secondary , Carcinoma, Lobular/surgery , Chemotherapy, Adjuvant , Combined Modality Therapy , Disease-Free Survival , Estrogens , False Negative Reactions , Female , Follow-Up Studies , Humans , Incidence , Lymph Node Excision , Lymphatic Metastasis/diagnostic imaging , Mastectomy/methods , Middle Aged , Neoplasm Staging , Neoplasms, Hormone-Dependent/diagnosis , Neoplasms, Hormone-Dependent/epidemiology , Neoplasms, Hormone-Dependent/secondary , Neoplasms, Hormone-Dependent/surgery , Progesterone , Prognosis , Radionuclide Imaging , Radiotherapy, Adjuvant , Retrospective Studies , Rosaniline Dyes , Sentinel Lymph Node Biopsy/methods , Survival Analysis , Technetium Tc 99m Sulfur Colloid
16.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 31(4): 173-177, jul.-ago. 2012. tab, ilus
Article in Spanish | IBECS | ID: ibc-100786

ABSTRACT

La biopsia selectiva del ganglio centinela (GC) es en la actualidad el procedimiento de elección en la estadificación axilar en cánceres de mama en estadios iniciales. El objetivo de este trabajo es establecer nuestra tasa de falsos negativos a lo largo de un período mínimo de 5 años de seguimiento de 258 pacientes con cáncer de mama estadificados mediante este procedimiento. Método. Estudio retrospectivo de 258 pacientes con cáncer de mama consecutivos T1-T2<3cm estadificados como pN0 mediante GC entre enero-2001 y diciembre-2005.Se empleó la técnica combinada isotópica y colorante para la detección. Fueron sometidos a seguimiento con un período mínimo de 5 años, la media fue 81 meses, siendo el punto final del seguimiento el 31 de diciembre de 2010. La evidencia de recurrencia axilar, recidiva tumoral en la mama, presencia de enfermedad a distancia, y muerte fueron los eventos recogidos y analizados. Resultados. De las 258 pacientes, se detectaron 3 falsos negativos (1,1%), con recurrencia axilar a los 10, 11 y 29 meses de la cirugía. En el análisis de supervivencia este hecho no tuvo repercusión significativa, a diferencia de la existencia de recidiva mamaria o la aparición de metástasis a distancia que ocurrieron en un 4,7 y un 6,2% de las pacientes. La supervivencia global relacionada con el cáncer fue de un 93,0% (240/258) y la supervivencia libre de enfermedad del 89,1% (230/258). Conclusión. El riesgo de recurrencia axilar tras un ganglio centinela negativo sin vaciamiento linfático completo es lo suficientemente bajo como para considerar a este procedimiento como de elección en la estadificación axilar del cáncer de mama en estadios iniciales. Además, permite alcanzar un adecuado control local de la enfermedad sin disminuir la supervivencia de los pacientes(AU)


The sentinel lymph node (SLN) biopsy is currently the procedure of choice for axillary node staging in initial stages of breast cancer. The purpose of this study is to establish our false negative rate within a 5-year follow-up period in 258 patients with breast cancer staged with this procedure. Methods. A retrospective study on 258 consecutive T1-T2<3cm pN0 staged breast carcinomas treated from January 1, 2001 to December 31, 2005 was performed. The combined technique of isotope plus blue dye was used for detection. The subjects underwent a minimum follow-up of 5 years, mean 81 months, with an end of follow-up at December 31, 2010. Evidence of axillary recurrence, tumor recurrence in the breast and signs of disease progression or death were the events collected and analyzed. Results. Of the 258 patients, 3 false negatives (1.1%) with axillary recurrence were detected at 10, 11 and 29 months of the surgery. This did not have a significant repercussion in the survival analysis on the contrary to the existence of breast recurrence or the appearance of distant metastasis in 4.7% and 6.2% patients, respectively. Global survival related with the cancer was 93.0 (240/258) and disease free survival was 89.1% (230/258). Conclusion. The risk of developing axillary recurrence after a negative SLN without axillary node dissection is low enough to consider the SLN procedure to be the best approach for axilla staging in early breast cancer. This staging technique also makes it possible to achieve local disease control without diminishing the survival of the patients(AU)


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Sentinel Lymph Node Biopsy/methods , Breast Neoplasms/epidemiology , Prognosis , Neoplasm Recurrence, Local/complications , Neoplasm Recurrence, Local/diagnosis , /instrumentation , /methods , Mastectomy/methods , Mastectomy , /trends , Immunohistochemistry/methods , Immunohistochemistry , Axilla/pathology , Axilla
17.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 31(2): 83-88, mar.-abr. 2012.
Article in Spanish | IBECS | ID: ibc-99643

ABSTRACT

Objetivo. Determinar la utilidad clínica de la gated-SPECT de perfusión miocárdica en la detección de isquemia silente en pacientes diabéticos sin síntomas ni eventos cardiovasculares previos y evaluar implicaciones pronósticas. Material y métodos. Estudio retrospectivo de 56 pacientes diabéticos asintomáticos tras una gated-SPECT de perfusión miocárdica para diagnóstico de enfermedad isquémica. El criterio de isquemia fue: ligera SDS<4, moderada SDS de 4 a 8, severa SDS>8. Se realizó un análisis estadístico multivariante para identificar variables predictoras de un estudio anormal y se registraron hasta diciembre de 2010 los eventos cardiovasculares. Resultados. Una alta proporción de los 56 pacientes presentó un estudio de perfusión anormal (46,4%), existiendo isquemia moderada-severa en el 10,7%, necrosis con isquemia en el 5,4% y necrosis en el 7,1%. No encontramos diferencias en cuanto al tipo de esfuerzo (tapiz rodante o dipiridamol). Existió una alta combinación de factores de riesgo cardiovascular. En el análisis multivariante, la nefropatía diabética fue la única que se relacionó con una SPECT anormal (p=0,043). En el seguimiento, los eventos fueron: 2 revascularizaciones precoces, 5 ingresos en cardiología, 10 muertes de no origen cardíaco. La existencia de isquemia en la SPECT se relacionó de forma significativa con la aparición de eventos cardiovasculares (p<0,05). Conclusión. La SPECT de perfusión miocárdica en diabéticos asintomáticos con alta asociación de factores de riesgo detecta la existencia de isquemia silente, la cual parece relacionarse con futuros eventos cardiovasculares. La nefropatía diabética sugiere mayor probabilidad de estudios anormales; sin embargo, es preciso establecer los criterios de cribado para un mayor rendimiento y un menor coste económico(AU)


Aim. To determine the clinical utility of the gated myocardial perfusion SPECT to detect silent ischemia in asymptomatic diabetic patients without previous coronary events and to evaluate the prognosis of this population. Material and methods. A retrospective study of 56 asymptomatic diabetics referred for a gated myocardial perfusion SPECT for diagnosis of ischemic disease was performed. The criteria for ischemia were: mild SDS<4, moderate SDS 4-8, severe SDS>8. A multivariable statistical analysis was carried out to identify possible predictive variables of an abnormal SPECT. The cardiovascular events were recorded up to December-2010. Results. A high proportion of the 56 patients had an abnormal perfusion study (46.4%), there being moderate-severe ischemia in 10.7%, necrosis with ischemia in 5.4% and necrosis in 7.1%. We found no statistical differences in the type of stress used (treadmill or dipyridamole). The patients had a high combination of cardiovascular risk factors. In the multivariate analysis, diabetic nephropathy was the only factor related to an abnormal SPECT (p=0.043). The events recorded in the follow-up were: 2 early revascularizations, 5 cardiology admissions, 10 non-cardiac related deaths. The existence of ischemia in the SPECT was significantly related to the appearance of cardiovascular events (p<0.05). Conclusion. A gated myocardial perfusion SPECT in asymptomatic diabetics with high combination of cardiovascular risk factors detects silent ischemia in a significant proportion and this seems to be related to future coronary events. Diabetic nephropathy implies a greater likelihood of abnormal studies. However, the screening criteria in this population still need to be established for better performance and lower cost(AU)


Subject(s)
Humans , Male , Female , Middle Aged , Heart Diseases/complications , Heart Diseases/diagnosis , Tomography, Emission-Computed, Single-Photon/instrumentation , Tomography, Emission-Computed, Single-Photon/methods , Perfusion/instrumentation , Perfusion/methods , Infusion Pumps , Risk Factors , Nuclear Medicine/methods , Nuclear Medicine/trends , Heart Diseases , Prognosis , Retrospective Studies , Multivariate Analysis , Radiopharmaceuticals
18.
Rev Esp Med Nucl Imagen Mol ; 31(2): 83-8, 2012.
Article in Spanish | MEDLINE | ID: mdl-21944188

ABSTRACT

AIM: To determine the clinical utility of the gated myocardial perfusion SPECT to detect silent ischemia in asymptomatic diabetic patients without previous coronary events and to evaluate the prognosis of this population. MATERIAL AND METHODS: A retrospective study of 56 asymptomatic diabetics referred for a gated myocardial perfusion SPECT for diagnosis of ischemic disease was performed. The criteria for ischemia were: mild SDS<4, moderate SDS 4-8, severe SDS>8. A multivariable statistical analysis was carried out to identify possible predictive variables of an abnormal SPECT. The cardiovascular events were recorded up to December-2010. RESULTS: A high proportion of the 56 patients had an abnormal perfusion study (46.4%), there being moderate-severe ischemia in 10.7%, necrosis with ischemia in 5.4% and necrosis in 7.1%. We found no statistical differences in the type of stress used (treadmill or dipyridamole). The patients had a high combination of cardiovascular risk factors. In the multivariate analysis, diabetic nephropathy was the only factor related to an abnormal SPECT (p=0.043). The events recorded in the follow-up were: 2 early revascularizations, 5 cardiology admissions, 10 non-cardiac related deaths. The existence of ischemia in the SPECT was significantly related to the appearance of cardiovascular events (p<0.05). CONCLUSION: A gated myocardial perfusion SPECT in asymptomatic diabetics with high combination of cardiovascular risk factors detects silent ischemia in a significant proportion and this seems to be related to future coronary events. Diabetic nephropathy implies a greater likelihood of abnormal studies. However, the screening criteria in this population still need to be established for better performance and lower cost.


Subject(s)
Diabetes Complications/epidemiology , Myocardial Ischemia/epidemiology , Myocardial Perfusion Imaging , Tomography, Emission-Computed, Single-Photon , Aged , Asymptomatic Diseases , Comorbidity , Diabetes Complications/diagnostic imaging , Diabetes Complications/mortality , Dipyridamole , Exercise Test , Female , Humans , Hypercholesterolemia/epidemiology , Incidence , Male , Middle Aged , Myocardial Ischemia/diagnostic imaging , Myocardial Revascularization/statistics & numerical data , Necrosis , Obesity/epidemiology , Organophosphorus Compounds , Organotechnetium Compounds , Patient Admission/statistics & numerical data , Predictive Value of Tests , Prognosis , Retrospective Studies , Risk , Smoking/epidemiology , Stroke Volume
SELECTION OF CITATIONS
SEARCH DETAIL
...